These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 19238604)

  • 1. ACP Journal Club. Telmisartan did not reduce a composite of CV death, MI, HF, or stroke in high-risk patients intolerant to ACE inhibitors.
    Taylor RJ
    Ann Intern Med; 2009 Feb; 150(4):JC2-6. PubMed ID: 19238604
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).
    Kappert K; Böhm M; Schmieder R; Schumacher H; Teo K; Yusuf S; Sleight P; Unger T;
    Circulation; 2012 Aug; 126(8):934-41. PubMed ID: 22829023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
    Böhm M; Baumhäkel M; Teo K; Sleight P; Probstfield J; Gao P; Mann JF; Diaz R; Dagenais GR; Jennings GL; Liu L; Jansky P; Yusuf S;
    Circulation; 2010 Mar; 121(12):1439-46. PubMed ID: 20231536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
    Verdecchia P; Sleight P; Mancia G; Fagard R; Trimarco B; Schmieder RE; Kim JH; Jennings G; Jansky P; Chen JH; Liu L; Gao P; Probstfield J; Teo K; Yusuf S;
    Circulation; 2009 Oct; 120(14):1380-9. PubMed ID: 19770395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACP journal club. In hemodialysis patients with CHF, adding telmisartan to standard ACE inhibitors reduced CHD mortality and admissions.
    Mustafa R; Garg AX
    Ann Intern Med; 2011 May; 154(10):JC5-05. PubMed ID: 21576523
    [No Abstract]   [Full Text] [Related]  

  • 6. ACP Journal Club. Stenting and endarterectomy for carotid artery stenosis did not differ for a composite of stroke, MI, or death.
    Kirshner HS
    Ann Intern Med; 2010 Nov; 153(10):JC5-12. PubMed ID: 21079207
    [No Abstract]   [Full Text] [Related]  

  • 7. Telmisartan shown to reduce cardiovascular death, myocardial infarction and stroke in ACE-intolerant high-risk patients.
    Cardiovasc J Afr; 2008; 19(5):275. PubMed ID: 18997991
    [No Abstract]   [Full Text] [Related]  

  • 8. ACP Journal Club. Adding clopidogrel to proton-pump inhibitors was not associated with increased CV risk after MI.
    Aronow HD
    Ann Intern Med; 2010 Dec; 153(12):JC6-13. PubMed ID: 21173402
    [No Abstract]   [Full Text] [Related]  

  • 9. Telmisartan for the management of patients at high cardiovascular risk.
    Ruilope LM
    Curr Med Res Opin; 2011 Aug; 27(8):1673-82. PubMed ID: 21718097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?
    Volpe M
    QJM; 2012 Jan; 105(1):11-27. PubMed ID: 22011630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ONTARGET/TRANSCEND Trial Programme: baseline data.
    Sleight P
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACP Journal Club. Review: ACE-Is or ARBs reduce adverse CV outcomes regardless of baseline systolic blood pressure.
    Singh V
    Ann Intern Med; 2012 Jul; 157(2):JC2-8. PubMed ID: 22801699
    [No Abstract]   [Full Text] [Related]  

  • 13. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.
    Verdecchia P; Dagenais G; Healey J; Gao P; Dans AL; Chazova I; Binbrek AS; Iacobellis G; Ferreira R; Holwerda N; Karatzas N; Keltai M; Mancia G; Sleight P; Teo K; Yusuf S;
    J Hypertens; 2012 May; 30(5):1004-14. PubMed ID: 22495138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACP Journal Club. Use of nonsteroidal antiinflammatory drugs was associated with increased risks for death and hospitalization for MI and HF.
    Siegel D
    Ann Intern Med; 2009 Jun; 150(12):JC6-12. PubMed ID: 19528557
    [No Abstract]   [Full Text] [Related]  

  • 15. ACP Journal Club. Review: ACE inhibitors reduce risk for pneumonia.
    Lipchik RJ
    Ann Intern Med; 2012 Nov; 157(10):JC5-2. PubMed ID: 23165678
    [No Abstract]   [Full Text] [Related]  

  • 16. ACP Journal Club. Extended follow-up in an HF clinic did not reduce death or hospital admission in stable systolic HF.
    DeWalt DA
    Ann Intern Med; 2012 Dec; 157(12):JC6-9. PubMed ID: 23247958
    [No Abstract]   [Full Text] [Related]  

  • 17. ACP Journal Club. Review: Aspirin does not reduce CV events but may reduce nonfatal stroke in peripheral artery disease.
    Mukherjee D
    Ann Intern Med; 2009 Sep; 151(6):JC3-5, JC3-4. PubMed ID: 19755351
    [No Abstract]   [Full Text] [Related]  

  • 18. ACP Journal Club. Telmisartan did not prevent recurrent stroke or major cardiovascular events.
    Sloan MA
    Ann Intern Med; 2009 Feb; 150(4):JC2-8, JC2-9. PubMed ID: 19238607
    [No Abstract]   [Full Text] [Related]  

  • 19. ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors.
    Farkouh M
    Ann Intern Med; 2010 Jun; 152(12):JC6-10. PubMed ID: 20547892
    [No Abstract]   [Full Text] [Related]  

  • 20. ACP Journal Club. In recently postmenopausal women, HRT reduced a composite of death, MI, or heart failure at 10 years.
    Cheung AM
    Ann Intern Med; 2013 Feb; 158(4):JC2. PubMed ID: 23420251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.